General Surgery and Organ Transplantation Unit, AOU Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
Department of Surgery, Division of Surgical Oncology, James Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Medicina (Kaunas). 2023 Mar 14;59(3):568. doi: 10.3390/medicina59030568.
: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developments in the setting of LT oncology, with particular attention to LT for unresectable colorectal liver metastases (CRLM) and cholangiocellular carcinoma (CCA). : A review of the recently published literature was conducted. : Growing evidence exists on the efficacy of LT in curing CRLM and peri-hilar and intrahepatic CCA in well-selected patients when integrating this strategy with (neo)-adjuvant chemotherapy, radiotherapy, or locoregional treatments. : For unresectable CCA and CRLM management, several prospective protocols are forthcoming to elucidate LT's impact relative to alternative therapies. Advances in diagnosis, treatment protocols, and donor-to-recipient matching are needed to better define the oncological indications for transplantation. Prospective, multicenter trials studying these advances and their impact on outcomes are still required.
肝移植(LT)是治疗多种原发性和继发性肝恶性肿瘤的最佳策略。近年来,人们对扩大移植肿瘤学适应证的兴趣日益浓厚。本文旨在综述 LT 肿瘤学领域的最新进展,特别关注不可切除结直肠肝转移(CRLM)和胆管细胞癌(CCA)的 LT。
对最近发表的文献进行了回顾。
越来越多的证据表明,在将该策略与(新)辅助化疗、放疗或局部区域治疗相结合的情况下,LT 对精心选择的患者的 CRLM 和肝门周围及肝内 CCA 具有治愈作用。
对于不可切除的 CCA 和 CRLM 管理,即将出台几项前瞻性方案,以阐明 LT 相对于其他治疗方法的影响。需要在诊断、治疗方案和供体与受体匹配方面取得进展,以更好地确定移植的肿瘤学适应证。仍需要前瞻性、多中心试验研究这些进展及其对结果的影响。